Mizuho Forecasts Strong Price Appreciation for Chemours (NYSE:CC) Stock

Chemours (NYSE:CC - Get Free Report) had its target price lifted by research analysts at Mizuho from $13.00 to $16.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an "outperform" rating on the specialty chemicals company's stock. Mizuho's target price would indicate a potential upside of 17.91% from the stock's current price.

Other research analysts also recently issued reports about the company. The Goldman Sachs Group dropped their price objective on Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Barclays dropped their price objective on Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 28th. Morgan Stanley dropped their price objective on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Finally, Royal Bank Of Canada increased their target price on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research report on Thursday, July 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $17.44.

Chemours Price Performance

Shares of NYSE CC traded down $0.10 during mid-day trading on Tuesday, hitting $13.57. 2,984,668 shares of the stock traded hands, compared to its average volume of 2,568,995. The company has a debt-to-equity ratio of 7.01, a current ratio of 1.75 and a quick ratio of 0.83. Chemours has a twelve month low of $9.13 and a twelve month high of $24.64. The company has a market cap of $2.03 billion, a PE ratio of 67.85 and a beta of 1.65. The firm has a 50 day simple moving average of $11.53 and a two-hundred day simple moving average of $13.86.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.36 billion. Chemours had a return on equity of 23.82% and a net margin of 0.54%. The firm's quarterly revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 earnings per share. As a group, equities research analysts forecast that Chemours will post 2.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Chemours news, CFO Shane Hostetter purchased 4,450 shares of the business's stock in a transaction on Monday, May 19th. The stock was acquired at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the completion of the transaction, the chief financial officer directly owned 59,694 shares in the company, valued at approximately $673,348.32. This represents a 8.06% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Damian Gumpel purchased 13,400 shares of the business's stock in a transaction on Monday, June 2nd. The shares were acquired at an average price of $9.22 per share, with a total value of $123,548.00. Following the completion of the transaction, the insider owned 123,879 shares of the company's stock, valued at approximately $1,142,164.38. This trade represents a 12.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders purchased 25,672 shares of company stock worth $251,573. 0.47% of the stock is owned by insiders.

Institutional Trading of Chemours

Several large investors have recently modified their holdings of CC. Charles Schwab Investment Management Inc. grew its stake in shares of Chemours by 6.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,302,272 shares of the specialty chemicals company's stock worth $22,008,000 after purchasing an additional 73,220 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Chemours by 6.8% in the fourth quarter. Victory Capital Management Inc. now owns 110,311 shares of the specialty chemicals company's stock worth $1,864,000 after purchasing an additional 7,052 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Chemours in the fourth quarter worth about $334,000. Raymond James Financial Inc. purchased a new stake in Chemours in the fourth quarter worth about $2,283,000. Finally, Swiss National Bank lifted its holdings in Chemours by 1.0% in the fourth quarter. Swiss National Bank now owns 293,500 shares of the specialty chemicals company's stock worth $4,960,000 after buying an additional 2,800 shares during the period. 76.26% of the stock is owned by institutional investors.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.